CLS AMERICAS


Associated tags: FDA, CLS, Prostate cancer, Urinary incontinence, Erectile dysfunction, Medical imaging, Diagnosis, Urology, Patient, Temperature, FLA, Physician, Prostate, MSP

Locations: CA, SWEDEN, US, SINGAPORE, AMERICAS, GERMANY

CLS Americas Announces 2nd Order of TRANBERG™ Focal Laser Ablation Accessories Placed by the National Institutes of Health Clinical Center

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, NIHCC, FLA, NIH, Male, Urinary incontinence, Erectile dysfunction, CLS, Bangladesh Technical Education Board, Medical imaging

LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.

Key Points: 
  • LOS ANGELES, April 09, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has received its second order from the National Institutes of Health Clinical Center (NIHCC) for its TRANBERG™ Thermal Therapy System accessories.
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • “This second order of our TRANBERG Focal Laser Ablation accessories enables our continued collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • It includes a desk-top mobile laser unit, innovative non-cooled laser applicators, tissue temperature probes, and procedure-specific accessories.

CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, March 28, 2024
Diagnosis, Temperature, Urology, Prostate cancer, Patient, Cancer, Prostate, FLA, Urinary incontinence, Erectile dysfunction, CLS, FDA, Physician, Medical imaging

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that ROSE Urology, LLC , located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Operating under CLS's Mobile Services Agreement, CLS will provide its FDA 510(k) cleared TRANBERG Laser, consumable accessories, training, and on-site clinical and technical support to ROSE Urology physicians and staff during procedures.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.

CLS Americas Selects Quest International to Provide Aftermarket Service and Logistics Operations for TRANBERG Laser Ablation System

Retrieved on: 
Tuesday, November 28, 2023
ED, Quest International, Risk, FLA, Service, Quest, Prostate cancer, Original equipment manufacturer, Urinary incontinence, CLS, Growth, Diagnosis, Urology, Erectile dysfunction, Medical imaging

LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has selected Quest International , a global aftermarket technical service provider to OEMs, to provide Service and Logistics Operations for the US market.

Key Points: 
  • LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced it has selected Quest International , a global aftermarket technical service provider to OEMs, to provide Service and Logistics Operations for the US market.
  • Under the agreement, Quest will provide end to end white glove service management including field services, depot repair, and warehousing and logistics support for CLS’s TRANBERG Thermal Therapy System , a 510(k) medical device for soft tissue ablation.
  • The CLS TRANBERG System provides safe and effective focal laser ablation of low-to-medium risk prostate tumors, while also preserving healthy tissue to minimize the risk of unwanted side effects such as ED and urinary incontinence.
  • “CLS Americas is very pleased to partner with Quest International and its excellent reputation and expertise in all aspects of aftermarket service and logistics operations,” stated Michael Magnani, president of CLS Americas.

CLS Americas States KASRAEIAN Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation

Retrieved on: 
Thursday, November 9, 2023
FDA, Erectile dysfunction, CLS, Temperature, FLA, Urology, Physician, Organization, Prostate cancer, FACS, Prostate, Microsoft mobile services, Cancer, Patient, Diagnosis, Urinary incontinence, Medical imaging

LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that KASRAEIAN Urology located in Jacksonville, FL, will begin treating prostate cancer patients using the TRANBERG™ Thermal Therapy System to provide focal laser ablation treatments.

Key Points: 
  • LOS ANGELES, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that KASRAEIAN Urology located in Jacksonville, FL, will begin treating prostate cancer patients using the TRANBERG™ Thermal Therapy System to provide focal laser ablation treatments.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We look forward to adding the TRANBERG focal laser ablation treatment option for our low-to-intermediate risk prostate cancer patients.
  • It allows them to gain access to our image-guided TRANBERG focal laser ablation system without any capital equipment expense,” said Michael Magnani, president of CLS Americas.

CLS Americas and HALO Diagnostics Initiate Prostate Cancer Clinical Study using TRANBERG Focal Laser Ablation System

Retrieved on: 
Tuesday, November 7, 2023
Trial of the century, Erectile dysfunction, CLS, ASC, FLA, Urology, Prostate cancer, ED, Quality of life, Risk, HALO, Patient, Diagnosis, Urinary incontinence, Medical imaging

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG™ Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients.

Key Points: 
  • LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO Diagnostics , a leader in precision diagnostics and image-guided therapies (HALO Dx), today announced a 25-patient clinical study using the TRANBERG™ Thermal Therapy System to perform image-guided focal laser ablation (FLA) of low-to-intermediate risk prostate cancer in patients.
  • The CLS TRANBERG System provides safe and effective focal laser ablation of low-to-medium risk prostate tumors, while also preserving healthy tissue to minimize the risk of unwanted side effects such as ED and urinary incontinence.
  • “CLS is pleased to collaborate with Dr. Scionti and HALO Diagnostics for this clinically significant study regarding the efficacy of treating prostate cancer using image-guided focal laser ablation in an ASC,” stated Michael Magnani, president of CLS Americas.
  • “HALO Diagnostic is excited to begin this clinically significant study with CLS Americas and to begin offering this safe and minimally invasive procedure with the new TRANBERG laser through our network.”

CLS Americas Announces Kearney Urology Center will use its TRANBERG Laser to Provide Focal Laser Ablation Treatments to Prostate Cancer Patients

Retrieved on: 
Tuesday, October 24, 2023
FDA, PC, Erectile dysfunction, CLS, Urology, Temperature, FLA, Mobile service, Physician, Prostate cancer, Prostate, Mobile Servicing System, Patient, Diagnosis, Urinary incontinence, Medical imaging

In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.

Key Points: 
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We are excited to begin offering this new minimally invasive focal laser ablation treatment to our patients with low-to-intermediate risk prostate cancer.
  • The CLS Laser is very precise, easy to operate, and the treatment workflow is similar to prostate cryotherapy procedures,” stated Garrett D. Pohlman, M.D., Kearney Urology Center.
  • “CLS Americas is pleased to provide the Kearney Urology Center, PC with the training, use, and clinical support of our TRANBERG focal laser ablation system,” stated Michael Magnani, president of CLS Americas.

CLS Americas Debuts Mobile Service Program for Office-Based Focal Laser Ablation at Western Section AUA Meeting

Retrieved on: 
Tuesday, October 3, 2023
Microsoft mobile services, Prostate cancer, CLS, MSP, Patient, Urology, Physician, Diagnosis, Erectile dysfunction, FDA, Urinary incontinence, Medical imaging

The TRANBERG system is designed to work with multiple MR/US fusion image guidance systems for precise and accurate tumor ablation in a minimally invasive, outpatient setting in a urology office or clinic.

Key Points: 
  • The TRANBERG system is designed to work with multiple MR/US fusion image guidance systems for precise and accurate tumor ablation in a minimally invasive, outpatient setting in a urology office or clinic.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
  • “We’re excited to provide our TRANBERG system to innovative urologists looking to add focal laser ablation to their practice without adding capital expense,” said Michael Magnani, president of CLS Americas.

CLS Americas Presents its TRANBERG™ System for Image-Guided Focal Laser Ablation at Focal Therapy Society 2023 Conference

Retrieved on: 
Thursday, September 7, 2023
Area studies, Microsoft mobile services, Temperature, Prostate, MSP, Physician, Diagnosis, Erectile dysfunction, FDA, Urinary incontinence, Conference, Prostate cancer, Medical imaging

WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- CLS Americas , a leading provider of office-based, focal laser ablation systems in the US urology market, today announced it will exhibit its TRANBERG™ Thermal Therapy System for focal laser ablation at the Focal Therapy Society Annual Meeting 2023 being held this September 7-9, 2023 in Washington, DC.

Key Points: 
  • WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- CLS Americas , a leading provider of office-based, focal laser ablation systems in the US urology market, today announced it will exhibit its TRANBERG™ Thermal Therapy System for focal laser ablation at the Focal Therapy Society Annual Meeting 2023 being held this September 7-9, 2023 in Washington, DC.
  • The system is FDA 510(k) cleared for soft tissue ablation in a urology setting.
  • Compared to other focal therapies, focal laser ablation therapy has demonstrated higher levels of precision and accuracy with lower risk of side effects, such as erectile dysfunction and urinary incontinence.
  • “CLS Americas is pleased to exhibit it’s latest TRANBERG focal laser ablation system at this year’s Focal Therapy Society 2023 Conference,” stated Michael Magnani, president of CLS Americas.

CLS Americas and Focalyx Co-Marketing Agreement for Image-Guided Focal Laser Ablation of Prostate Tumors Using TRANBERG and Focalyx Fusion Systems

Retrieved on: 
Monday, August 28, 2023
Microsoft mobile services, Prostate cancer, Cryotherapy, Prostate, MSP, FLA, Patient, Physician, Risk, Urology, Diagnosis, Erectile dysfunction, ED, Urinary incontinence, Medical imaging

IRVINE, Calif. and MIAMI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- CLS Americas , a leading provider of office-based, focal laser ablation systems in the US urology market, and Focalyx® today announced a co-marketing agreement to sell and market their integrated, minimally invasive, fusion-guided focal laser ablation treatment for low-to-intermediate risk prostate cancer patients.

Key Points: 
  • IRVINE, Calif. and MIAMI, Aug. 28, 2023 (GLOBE NEWSWIRE) -- CLS Americas , a leading provider of office-based, focal laser ablation systems in the US urology market, and Focalyx® today announced a co-marketing agreement to sell and market their integrated, minimally invasive, fusion-guided focal laser ablation treatment for low-to-intermediate risk prostate cancer patients.
  • Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
  • The Focalyx® system will enable both companies to offer and support our complementary solutions for image-guided focal laser ablation,” stated Michael Magnani, President of CLS Americas.
  • Bianco’s earlier results from our twenty patient feasibility study using our TRANBERG Thermal Therapy System with Focalyx® for image guidance were positive.

CLS Americas Announces the National Institutes of Health Clinical Center Placed its 1st Order of the TRANBERG™ Thermal Therapy System for its Research Study - MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer

Retrieved on: 
Thursday, June 1, 2023
Male, National Institutes of Health Clinical Center, NIHCC, CLS, Temperature, Bangladesh Technical Education Board, FLA, Patient, Urology, Diagnosis, Erectile dysfunction, NIH, Urinary incontinence, Prostate cancer, Medical imaging

The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.

Key Points: 
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “CLS is pleased to begin this collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • A TRANBE RG FLA Animation Video of the system and procedure is available to watch.